In a push to find better biofuels to reduce gasoline consumption and lower greenhouse-gas emissions, scientists have genetically engineered E. coli that is highly efficient in producing butanol, a promising new type of biofuel. The new technology could speed up the development of butanol biofuels into a cost-effective alternative to ethanol.
While ethanol is the main biofuel on the market today, energy firms are increasingly looking to alternatives such as butanol. “It has many attractive properties,” says Jim McMillan, manager of biorefining process R&D at the National Renewable Energy Laboratory’s National Bioenergy Center, in Golden, CO. Because butanol packs more energy per gallon than ethanol does, cars running on butanol get better mileage. And, unlike ethanol, it doesn’t mix with water, so it can be shipped in existing petroleum pipelines without causing problems.
A number of research groups are engineering microbes that can convert sugar from various feedstocks into butanol. Most of these groups rely on the bacterium Clostridium acetobutylicum, which naturally makes a form of butanol called 1-butanol. “But Clostridium is not easy to deal with,” says James Liao, a chemical engineer at the University of California, Los Angeles. “It grows slowly, it’s very fastidious, and it’s not easy to genetically manipulate.” Despite decades of tinkering by scientists, the microbe still can’t produce enough butanol to make it economically viable as a transportation fuel, Liao says.
Instead, he and his colleagues turned to E. coli. Although the bacterium does not produce butanol naturally, it is easy to modify and grows fast. Instead of tweaking the pathway that the microbes employ for fermenting sugar into alcohol, Liao reasoned that he could program E. coli to produce butanol by diverting some of the microorganism’s metabolites into alcohol production. These metabolites, called keto acids, are involved in the synthesis of amino acids, the building blocks of proteins.
To make butanol from keto acids, the researchers inserted two different nonnative genes into E. coli. The first gene came from a microbe commonly used in the production of cheese. The gene codes for an enzyme that converts keto acids into aldehydes. The second gene, derived from yeast, codes for an enzyme that converts aldehydes into butanol.
Initially, when linked together in E. coli, the two genes allowed the microbe to produce small amounts of butanol. With further genetic modifications, Liao was able to dramatically increase the efficiency of the process. For instance, deleting certain genes and boosting the activity of others increased the amount of keto acids available for conversion into butanol. With all the combined manipulations, the engineered microbes achieved an efficiency high enough for industrial use, says Liao.
Gevo, a biofuels startup based in Pasadena, CA, has acquired an exclusive license to commercialize Liao’s technology. (Liao is on the company’s scientific advisory board.) “It’s a real breakthrough,” says Mathew Peters, Gevo’s chief scientific officer. Not only did Liao improve the efficiency of the process, but he also designed his microbes to produce a particular form of butanol called isobutanol. “We believe isobutanol is a superior fuel,” says Peters. Compared with 1-butanol, isobutanol has a higher octane number, which reduces knocking in the vehicle’s engine.
What’s more, the biochemical pathway Liao designed for making isobutanol can be transferred to other microbes. In addition to investigating E. coli, Gevo is looking at different microorganisms that could be modified in the same way. “We’re interested in any organism that will make the process cheaper,” says Peters.
Gevo isn’t alone in its pursuit of a better butanol-producing bug. In June 2006, BP and DuPont joined efforts to develop butanol. .
Last June, BP and DuPont, along with Associated British Foods, announced their plans to build a biobutanol pilot plant at an existing BP site in England. The plant, which will use sugar beet as a feedstock, is expected to begin operations in 2009, with the ultimate goal of commercializing butanol after 2010.
According to Peters, Gevo plans to make a decision by the end of the year on whether to go ahead with its own plans to build a butanol plant. In the meantime, certain technological hurdles still need to be overcome to make butanol cost competitive, he says. Mainly, the microbes need to get faster at producing butanol, and their tolerance to isobutanol, which is toxic to the organisms, must improve. Still, Peters expects Gevo to resolve these issues in the coming months.
This startup wants to copy you into an embryo for organ harvesting
With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.
This artist is dominating AI-generated art. And he’s not happy about it.
Greg Rutkowski is a more popular prompt than Picasso.
VR is as good as psychedelics at helping people reach transcendence
On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.
This nanoparticle could be the key to a universal covid vaccine
Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.